Open an Account
search icon
2
NOTIFICATIONS
Best Algo trading app in India
Bigul

SEQUENT SCIENTIFIC LTD. - 512529 - Announcement under Regulation 30 (LODR)-Newspaper Publication

 In continuation to our intimation dated March 10, 2022 and pursuant to Regulation 47 of SEBI (LODR) Regulations, 2015, please find enclosed copies of the newspaper advertisement regarding completion of dispatch of Notice of Postal Ballot dated January 14, 2022, published on March 11, 2022 in Financial Express (English language-All edition) and Mumbai Lakshadeep (Marathi language-Mumbai edition). A copy of said advertisement is also hosted on the Company's website at www.sequent.in Kindly take the same on record.
12-03-2022
Bigul

SEQUENT SCIENTIFIC LTD. - 512529 - Shareholder Meeting / Postal Ballot-Notice of Postal Ballot

 We enclose herewith the Postal Ballot Notice dated January 14, 2022 along with Explanatory Statement. In compliance with the applicable circulars issued by the Ministry of Corporate Affairs and the Securities and Exchange Board of India, the Postal Ballot Notice is being sent to the Members of the Company who have their email ids registered with the Company/Depositories and whose names appear in the Register of Members/List of Beneficial Owners as received from Depositories as on Friday, March 04, 2022 through electronic mode only. The Postal Ballot Notice is also uploaded on the Company's website at www.sequent.in. Please note that the remote e-voting period in respect of the resolution mentioned in the Postal Ballot Notice will commence on Friday March 11, 2022 at 9:00 a.m. (IST) and ends on Saturday, April 09, 2022 at 5:00 p.m. (IST). Please consider this as compliance under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
10-03-2022
Bigul

SEQUENT SCIENTIFIC LTD. - 512529 - Announcement under Regulation 30 (LODR)-Updates on Acquisition

 With reference to our announcement dated December 16, 2021, on proposed acquisition of 100% stake in Nourrie Saude e Nutricao Animal Ltda ('Nourrie') through Alivira Saude Animal Ltda, Brazil, (erstwhile known as Evance Saude Animal Health Ltda), wholly owned subsidiary of the Company, we would like to inform you that the said transaction has been completed. On completion of the said transaction, Nourrie has become a Wholly Owned Subsidiary of Alivira Saude Animal Ltda and consequently of the Company. A press being issued by the Company is also attached herewith. We request you to take the above on your record
02-03-2022
Bigul

SEQUENT SCIENTIFIC LTD. - 512529 - Intimation Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations & Disclosure Requirements) Regulations, 2015 - Grant Of Stock Options To Eligible Employees Of The Company And Its Subsidiaries Under ''Sequent Scientific Employee Stock Option Plan 2020''

 The Nomination and Remuneration Committee of the Board of Directors, at their meeting held on February 22, 2022, has granted 10,00,000 Class A Options to the eligible employees under 'SeQuent Scientific Employee Stock Option Plan 2020' at an exercise price of Rs. 86/- (Rupees Eighty-Six Only) per share. The said options are convertible into equivalent number of equity shares of Rs. 2/- each of the Company, on exercise. The vesting period of these options is in a phased manner over a period of 5 years and on vesting, is exercisable within a period of 1 (one) year from the date of vesting. We request you to take the above on your record.
23-02-2022
Bigul

Q3FY22 Quarterly Result Announced for Sequent Scientific Ltd.

 Pharmaceuticals firm Sequent Scientific declares Q3FY22 result: Revenues at Rs 3,580 Million, PAT after minority interest at Rs 171 Million Commenting on the Company’s performance, Manish Gupta, Managing Director stated “Q3 reflects the beginning of a recovery in business across both APIs and formulations. We saw a strong growth in our formulations business, which grew 18.5% on constant currency basis, driven by scale up across our key markets - Brazil, India, and Turkey. On API side, we had strong orderbook & dispatches. However, port congestion challenges impacted ~15% of dispatches, depressing revenues, and thereby overall profitability. While the cost environment continues to be concerning for the industry, our concerted efforts towards price increases have started reflecting in our financial performance and we expect to see full benefit from Q4 FY22. Performance in Turkey in a volatile currency environment is significant. Our robust manufacturing footprint in the country makes us extremely confident of our continuing growth in local and export markets. Overall, we stay extremely confident of our unique, multi-pillar business model and envisage strong recovery in Q4 led by our API business and normalization of performance across revenues and profitability in FY23.” Result PDF
14-02-2022
Bigul

SEQUENT SCIENTIFIC LTD. - 512529 - Announcement under Regulation 30 (LODR)-Newspaper Publication

 Dear Sir/ Madam, Pursuant to the provision of Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed copies of advertisement published on February 13, 2022 in 'Financial Express' and 'Mumbai Lakshadeep' newspaper providing Extracts of Unaudited Financial Results of the Company for the quarter and nine months ended December 31, 2021
13-02-2022

Earnings Call for Q3FY22 of Sequent Scientific

 Conference Call with Sequent Scientific Management and Analysts on Q3FY22 Performance and Outlook. Listen to the full earnings transcript.
12-02-2022
Bigul

SEQUENT SCIENTIFIC LTD. - 512529 - Outcome Of Board Meeting Held On February 11, 2022, Along With Unaudited Standalone & Consolidated Financial Results And Press Release For The Quarter And Nine Months Ended December 31, 2021

 Pursuant to Regulation 30 (read with Part A of Schedule III) and Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Board of Directors at its Meeting held today, inter-alia, considered and approved the Unaudited Standalone and Consolidated Financial Results for the quarter and nine months ended December 31, 2021.
11-02-2022
Bigul

SEQUENT SCIENTIFIC LTD. - 512529 - Board Meeting Outcome for Outcome Of Board Meeting Held On February 11, 2022, Along With Unaudited Standalone & Consolidated Financial Results And Press Release For The Quarter And Nine Months Ended December 31, 2021

 Pursuant to Regulation 30 (read with Part A of Schedule III) and Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Board of Directors at its Meeting held today, inter-alia, considered and approved the Unaudited Standalone and Consolidated Financial Results for the quarter and nine months ended December 31, 2021.
11-02-2022
Bigul

SEQUENT SCIENTIFIC LTD. - 512529 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

 Dear Sir/ Madam, Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, kindly note that the Company has, as a part of its investors engagement activities, scheduled a conference call with the Analysts / Investors on Saturday, February 12, 2022, to discuss its Q3FY22 financial results. The Conference call details are enclosed. Eevnt - Post Results Q3FY22 Conference Call Date and Time - Saturday, February 12, 2022 at 9:30 A.M. Phone Nubers +91 22 6280 1263 +91 22 7115 8213
04-02-2022
Next Page
Close

Let's Open Free Demat Account